REGN Regeneron Pharmaceuticals
Dupixent's growth offsets Eylea's decline; the price is fair, with no clear margin of safety.
The story
Regeneron is a science-led biotech whose cash engine has shifted from Eylea, now eroding under biosimilar and Vabysmo pressure, to Dupixent, which it shares with Sanofi and which keeps expanding into new type 2 inflammation indications (COPD, CSU, others). Libtayo, Eylea HD and a deep antibody and genetics pipeline (obesity, oncology bispecifics, Factor XI) give it a long reinvestment runway. It is a mature but still-growing franchise. R&D intensity is structurally high and the Dupixent profit split caps how much margin it can expand.
Growth of about 6% reflects Dupixent and pipeline gains net of Eylea erosion, consistent with the roughly 5.6% five-year CAGR. Margin holds near the 33-37% recent range rather than the 2021-22 peak because R&D spending stays heavy. Sales-to-capital is set at 0.8, above the reported 0.47, which is inflated by cash and investments, and a 10-year horizon credits the Dupixent and antibody-platform moat.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 34.0% |
| Years to target margin | 4 |
| Sales-to-capital | 0.80 |
| Beta | 0.95 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.1% |
| Terminal WACC | 9.4% |
Valuation bridge
| PV of explicit FCFF | 30.02B |
| PV of terminal value | 37.08B |
| Equity value | 66.87B |
| ÷ shares → per share | $649.47 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 16.47B | 6.0% | 33.7% | 4.78B | 1.17B | 3.62B | 3.31B |
| 2 | 17.40B | 5.7% | 33.8% | 5.07B | 1.17B | 3.90B | 3.27B |
| 3 | 18.33B | 5.3% | 33.9% | 5.35B | 1.16B | 4.19B | 3.22B |
| 4 | 19.24B | 5.0% | 34.0% | 5.64B | 1.15B | 4.49B | 3.16B |
| 5 | 20.14B | 4.7% | 34.0% | 5.90B | 1.12B | 4.78B | 3.08B |
| 6 | 21.02B | 4.3% | 34.0% | 6.15B | 1.09B | 5.06B | 2.99B |
| 7 | 21.86B | 4.0% | 34.0% | 6.40B | 1.05B | 5.35B | 2.90B |
| 8 | 22.66B | 3.7% | 34.0% | 6.63B | 1.00B | 5.63B | 2.80B |
| 9 | 23.41B | 3.3% | 34.0% | 6.86B | 944.05M | 5.91B | 2.69B |
| 10 | 24.11B | 3.0% | 34.0% | 7.06B | 877.97M | 6.18B | 2.58B |
Key risks
- Faster Eylea/Eylea HD erosion from biosimilars and Vabysmo
- Dupixent competition from oral and next-gen type 2 inflammation drugs ahead of its 2031+ LOE
- Pipeline failures (obesity, oncology bispecifics) and IRA drug-price negotiation
Catalysts
- Dupixent label expansions and Phase 3 readouts in obesity, Factor XI and itepekimab
- Eylea HD prefilled syringe and dosing approvals stabilizing the ophthalmology franchise